Tural, D. Et Al. 2013. Clinical significance of p95HER2 Overexpression, PTEN loss and PI3K expression in p185HER2-positive metastatic breast cancer patients treated with trastuzumab-based therapies. European Cancer Congress 2013 - 17th ECCO / 38th ESMO / 32nd ESTRO , (Amsterdam, Netherlands).

Tural, D., Demirelli, F., Serdengecti, S., Ozturk, T., Ilvan, S., Turna, H., ... Ozguroglu, M.(2013). Clinical significance of p95HER2 Overexpression, PTEN loss and PI3K expression in p185HER2-positive metastatic breast cancer patients treated with trastuzumab-based therapies . European Cancer Congress 2013 - 17th ECCO / 38th ESMO / 32nd ESTRO, Amsterdam, Netherlands

Tural, D. Et Al. "Clinical significance of p95HER2 Overexpression, PTEN loss and PI3K expression in p185HER2-positive metastatic breast cancer patients treated with trastuzumab-based therapies," European Cancer Congress 2013 - 17th ECCO / 38th ESMO / 32nd ESTRO, Amsterdam, Netherlands, 2013

Tural, D. Et Al. "Clinical significance of p95HER2 Overexpression, PTEN loss and PI3K expression in p185HER2-positive metastatic breast cancer patients treated with trastuzumab-based therapies." European Cancer Congress 2013 - 17th ECCO / 38th ESMO / 32nd ESTRO , Amsterdam, Netherlands, 2013

Tural, D. Et Al. (2013) . "Clinical significance of p95HER2 Overexpression, PTEN loss and PI3K expression in p185HER2-positive metastatic breast cancer patients treated with trastuzumab-based therapies." European Cancer Congress 2013 - 17th ECCO / 38th ESMO / 32nd ESTRO , Amsterdam, Netherlands.

@conferencepaper{conferencepaper, author={D. Tural Et Al. }, title={Clinical significance of p95HER2 Overexpression, PTEN loss and PI3K expression in p185HER2-positive metastatic breast cancer patients treated with trastuzumab-based therapies}, congress name={European Cancer Congress 2013 - 17th ECCO / 38th ESMO / 32nd ESTRO}, city={Amsterdam}, country={Netherlands}, year={2013}}